Skip to main content
OpenTrials
Completed

NCT Number: NCT01700127

Predictors of Poor Immune Response to Rotavirus Vaccine in Infants

This will be a randomized study with the primary objective of assessing the impact of withholding versus encouraging breastfeeding on the immunogenicity of Rotarix® in infants.

Enrolled subjects will all be administered Rotarix®, at ages 6 to 7 weeks, and at10 -14 weeks. The subjects will be randomized into one of the two study arms. In one of the group caregivers will be advised to breastfeed immediately prior to and after each dose of the vaccine while in the other group caregivers will be advised to withhold breastfeeding for 30 minutes before and after each dose of the vaccine. The other childhood vaccines i.e. OPV and Pentavalent will be administered at least 30 minutes after administration of Rotarix®, The enrolled subjects will be followed up for 4 weeks after the 2nd dose of Rotarix®.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 week–7 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for Health Research and Development Society for Applied Studies

New Delhi, National Capital Territory of Delhi, 110016, India

About this study

Infants ≤7 weeks and pregnant women will be identified through a household survey.Families of infants aged 6-7 weeks will be called to the study clinic for consenting, screening and enrollment.All enrolled subjects will be administered 2 doses of Rotarix® at 6 to 7 weeks and at 10-14 weeks of age. Other childhood vaccines will also be offered.

At enrollment, a blood specimen and breast milk specimen will be obtained from the mother and a blood, salivary and stool specimens will be obtained from the subject before administering the Rotarix® vaccine.

At the time of the 2nd administration, a breast milk specimen will be obtained from the mother and a salivary specimen will be obtained from the subject before administering the Rotarix® vaccine. At 28 days (±) 5 after the 2nd dose of Rotarix® vaccine, a blood, salivary and stool specimen will be obtained from the subject.

Whenever the family comes to the study clinic at 6-7 weeks, consent will be administered and a clinical examination conducted.If the family is willing for the mother and the child to be part of the study and the child meets the eligibility criteria, the child will be enrolled.

Depending on the group allocation the mothers will be advised to withhold or encourage breastfeeding for 30 minutes before and after receipt of Rotarix®.

subjects will be observed for 30 minutes after receipt of the vaccines to assess for immediate adverse events.

All minor illnesses that do not require hospital referral will be managed by the study physician using current practices.

All hospitalizations and deaths will be reported and reviewed by an Independent Safety Monitor.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least one parent(s) or legally acceptable representative's consent for participation and are able to understand study procedures
  • Subjects aged 6 to 7 weeks at recruitment
  • No plans to move in the next 4 months
  • Weight for age not ≤ -3 SD of WHO child growth standards

Exclusion criteria

  • Infant not breastfed
  • Administration of rotavirus vaccine in the past
  • Known immunodeficiency disease, including HIV infection in the subject or the mother
  • Known chronic enteric disease
  • Diarrhea on the day of enrollment (temporary exclusion)
  • Any illness requiring hospitalization (temporary exclusion)
  • Any other conditions which in the judgment of the investigator warrant exclusion (e.g. no exclusion criteria but seems 'ill', investigators suspects neglect)

Treatment and study plan

breastfeeding

Other

breastfeeding encouraged versus withheld

Primary outcomes

  1. Proportion of subjects who seroconvert as measured by a 4-fold rise in serum anti-VP6 IgA antibodies between baseline and 4 weeks after the second dose of Rotarix®.

    Time frame: 14-18 weeks of age

Secondary outcomes

  1. Concentration of anti-VP6 antibodies in saliva of subjects before the first and second dose of Rotarix®. Proportion of subjects with enteric pathogens detected in stools. Vitamin D status of subjects enrolled in the study.

    Time frame: 14-18 weeks of age

Other outcomes

  1. Concentration of anti-VP6 antibodies in subjects and maternal serum at baseline and in subjects 4 weeks after the second dose of Rotarix®. Geometric mean titers of anti-VP6 IgG antibodies in maternal serum at baseline

    Time frame: upto 14-18 weeks of age

Sponsors and collaborators

Lead sponsor

Society for Applied Studies

Other

Collaborators

  • Christian Medical College, Vellore, India
  • Norwegian Institute of Public Health

Registry information

Acronym: PPIR

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Oct 4, 2012
Registry last updated
Jun 26, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.